Ambulatory Specialty Model (ASM)

Analysis updated November 9, 2026

Strategic questions for your team

What is our current Medicare Part B revenue exposure under ASM's two-sided risk arrangement, and can our organization absorb a payment adjustment of up to -9% in performance years 2027–2028, escalating to -12% by performance year 2031 — and have we modeled the net dollar impact across all ASM-eligible specialists at our TIN(s)?
Have we confirmed which of our individual physicians (by TIN/NPI combination) appear on the final ASM Participants dataset, verified they meet the ≥20 attributed episode-based cost measure (EBCM) episodes threshold, and determined whether they practice in one of the selected mandatory geographic areas (approximately one-quarter of CBSAs and metropolitan divisions)?
Does our EHR infrastructure support all required eCQM and MIPS CQM reporting for the applicable cohort-specific quality measures — including Heart Failure measures (MIPS Q492, Q008, Q005, Q236, Q377) and Low Back Pain measures (MIPS Q238, Q134, Q128, MIPS 182, plus the administrative claims-based MRI Lumbar Spine measure) — and can we meet the 75% data completeness threshold and ≥20-case minimum required for measures to be scored rather than receiving zero points?
Have we established — or do we have the operational capacity to establish within the first 90 days of the 2027 performance year — at least one written, signed Collaborative Care Arrangement (CCA) with each primary care practice that shares ASM beneficiaries, covering a minimum of three of the five required collaborative elements (data sharing, co-management, transitions in care planning, closed-loop communication, care coordination integration), and do we have contemporaneous documentation systems in place for the mandatory six-year records retention requirement?
Are our ASM-eligible specialists prepared to attest to both Improvement Activities (IA-1: Connecting to Primary Care and HRSN Screening, and IA-2: Establishing CCAs) for a continuous 90-day period within each performance year, and have we configured EHR workflows to confirm PCP access, transmit post-visit clinical summaries, and determine whether annual HRSN screening has occurred — recognizing that failure to complete both IAs results in a -20-point final score adjustment?
For the 2027 performance year, have we submitted our CEHRT ID and designated a continuous 180-day performance period to earn the full 100% Promoting Interoperability category score under the transition policy, and are we prepared for the more rigorous 2028 requirements — including mandatory HIE reporting under one of three options, the Electronic Prior Authorization measure, and the Electronic Prior Authorization for Prescription Drugs measure — given that a 'no' response or missing attestation results in a zero-percent PI category score?
Given that quality and cost each carry 50% weight in the final score calculation and that payment adjustments are determined by cohort-relative performance (not absolute benchmarks), have we obtained the enhanced episode-based cost measure data from CMS to benchmark our specialists' Heart Failure (COST_HF_1) and Low Back Pain (COST_LBP_1) EBCM performance against peers, and do we have a strategy to reduce avoidable hospitalizations and unnecessary procedures that drive episode cost outlier status?
Do any of our ASM-eligible specialists qualify for the 5-point rural scoring adjustment, the 10-point small practice bonus (2–15 NPIs in the TIN), the 15-point solo practitioner bonus, or the up to 10-point complex patient adjustment based on HCC risk scores and dual-eligible patient proportions — and have we mapped these adjustments against each physician's projected final score to identify who is at risk of falling below the cohort median and triggering a negative payment adjustment?
If any of our ASM participants change their billing TIN affiliation during a performance year, change their primary specialty designation to a qualifying cardiology subspecialty (e.g., cardiac electrophysiology, interventional cardiology, advanced heart failure and transplant cardiology), or are terminated by CMS, do we have a governance process to monitor Medicare enrollment data, evaluate exception eligibility, and manage the MIPS reporting obligations that re-activate upon exception — along with the loss of the CMS-sponsored model arrangements safe harbor protection for remuneration attributable to the exception period?
Have we evaluated whether ASM participation, including the requirement to establish CCAs with primary care practices, creates strategic care coordination infrastructure that could be leveraged across concurrent ACO participation (e.g., MSSP), other CMMI Advanced APM participation, or value-based contract arrangements with Medicare Advantage plans — and does our organization have a data governance framework in place to manage the Data Sharing Agreement (DSA) and Data Request and Attestation (DRA) required to access CMS beneficiary-identifiable claims data, including downstream disclosure restrictions to CCA primary care practice partners?
Given that multiple national organizations — including MGMA, AHA, and Premier — have formally urged CMS to delay the ASM launch citing outstanding operational and technical challenges as of late October 2026, has our organization assessed the realistic probability and potential timing of a launch delay, and do we have a contingency plan that addresses both a scenario in which the 2027 start date holds and one in which CMS grants a delay — including how a delay would affect our care coordination infrastructure investments, staffing plans, and CCA execution timelines?
In light of the AHA and coalition advocacy on proposed revisions to ASM as of October 2026, are we actively monitoring the rulemaking and stakeholder comment process for structural changes to the model — such as modifications to mandatory geographic area selection, episode-based cost measure thresholds, or payment adjustment rates — and do we have a mechanism to rapidly reassess our financial exposure and operational readiness if CMS finalizes revisions before the 2027 performance year launch?

Traps and concerns

Two-Year Payment Lag Compounds Revenue Volatility
ASM's payment architecture creates a structural cash-flow hazard: performance year 2027 (Jan 1–Dec 31, 2027) does not generate payment adjustments until payment year 2029 (Jan 1–Dec 31, 2029). This 24-month lag means a physician who underperforms in Year 1 carries a negative adjustment—up to -9% on all Medicare Part B covered professional services—into 2029 without any intervening opportunity to correct course before financial consequences land. For a cardiologist billing $500,000 annually in Part B, a -9% adjustment equals -$45,000 in Year 1 risk, escalating to -12% (-$60,000 at same billing volume) by payment year 2033 for Year 5. Because the adjustment applies to ALL covered Part B claims—not just heart failure episodes—a low performer faces revenue drag across their entire Medicare book of business, not just the targeted condition. CFOs must model this tail risk in multi-year operating budgets and ensure liquidity reserves are established before Year 1 begins.
Mandatory Participation Trap for TIN-Switching Specialists
ASM participants are identified by a TIN/NPI combination. If a selected specialist stops reassigning Medicare billing rights to the TIN under which they were selected—whether through practice acquisition, employment change, or group restructuring—the organizational change exception is triggered and they lose access to all ASM waivers (including the MIPS exemption and telehealth geographic waiver) for that performance year and all remaining years, unless they resume billing under the original TIN and re-qualify. Critically, a TIN-change exception does not eliminate obligations under another TIN/NPI combination—meaning a physician who bills under two TINs could remain mandatory under the second TIN even after the first is excepted. Health systems undergoing mergers, acquisitions, or practice-group restructuring during 2027–2031 must conduct TIN-level impact analyses before any organizational change is finalized, as mid-year restructuring can inadvertently strand specialists in a negative-adjustment posture without the benefit of model safe harbors.
Quality Zero-Score Trap from Data Completeness Failure
The ASM quality scoring methodology penalizes incomplete reporting with a zero score for any measure where fewer than 75% of eligible cases are reported. Quality represents 50% of the final score, and a final score of zero triggers the maximum negative payment adjustment (up to -12% by Year 5). For a heart failure participant, the five required quality measures include eCQM and MIPS CQM collection types (e.g., MIPS Q008, Q005, Q236, Q377) and an administrative claims-based measure (MIPS Q492). Participants must report at the individual TIN/NPI level (unless in a small practice of ≤15 NPIs), meaning every clinician's EHR must independently meet the 75% data completeness threshold. A single EHR misconfiguration, interface failure, or vendor gap in eCQM certification can silently suppress measure data below threshold—producing zero points on that measure without any real-time alert. Practices must validate eCQM reporting infrastructure against 2027 measure specifications (published Fall 2026) well in advance of the March 31, 2028 data submission deadline, and conduct mid-year audits against the 75% completeness floor.
Collaborative Care Arrangement Legal and Documentation Exposure
IA-2 requires each ASM participant to execute at least one written, signed, and dated Collaborative Care Arrangement (CCA) with a primary care practice sharing at least one ASM beneficiary, covering at least 3 of 5 specified collaborative elements. The CCA must be active for a continuous 90-day period within each performance year. Failure to attest to both improvement activities results in a -20-point final score penalty; failure on one IA costs -10 points. Beyond the scoring risk, any CCA that includes remuneration triggers additional compliance obligations under the CMS-sponsored model arrangements safe harbor (42 CFR §1001.952(ii)), including: payment cannot exceed the participant's ASM payment adjustment factor multiplied by their Medicare Part B payments for covered services in the applicable performance year (calculated separately per participant under the 2027 final rule), and payment must be made by check, electronic funds transfer, or other traceable cash transaction. Organizations must retain contemporaneous CCA documentation—including the identity of each party, remuneration value, valuation methodology, and exchange date—for at least 6 years per 42 CFR §512.135. Inadequate documentation exposes participants to audit findings that could void safe harbor protection and trigger Anti-Kickback Statute liability.
Promoting Interoperability Transition Cliff from 2027 to 2028
The 2027 final rule creates a one-year PI transition policy that is deceptively permissive: in 2027, participants need only submit their CEHRT ID and document a continuous 180-day performance period to receive a 100% PI category score. However, starting January 1, 2028, full Promoting Interoperability requirements become mandatory—participants must report all applicable objectives and measures (including both the Electronic Prior Authorization measure and the Electronic Prior Authorization for Prescription Drugs measure), satisfy one of three HIE reporting options, and submit required attestations. A 'no' response or failure to submit a required attestation or applicable exclusion results in a zero-percent PI category score, which generates a 0- to -10-point final score adjustment. Practices that treat 2027 as a 'free pass' and defer EHR upgrades, HIE connectivity, and e-prescribing workflow development will face a full-compliance cliff on January 1, 2028—with insufficient lead time to remediate. EHR vendors, interface engine vendors, and HIE connectivity should be contracted and tested during 2027 to ensure 2028 readiness.
Episode Attribution Volatility Threatening Eligibility and Scoring
ASM participant eligibility is re-evaluated annually using EBCM episode data from the calendar year two years prior to each performance year (e.g., CY 2025 data governs 2027 eligibility; CY 2026 data governs 2028 eligibility). The 20-episode minimum threshold means that a specialist whose patient panel shifts—due to retirement, panel changes, geographic relocation, or payer mix changes reducing Original Medicare volume—could fall below the threshold mid-model and trigger an eligibility re-determination. Additionally, cost scoring requires at least 20 EBCM episodes; participants with fewer episodes receive no cost performance category score, which eliminates 50% of the final score and prevents scoring in the quality and cost categories required for a non-zero final score and a non-neutral payment adjustment. For low back pain participants, service location is determined by the most common CBSA from attributed episodes—meaning a physician who expands into a new geography mid-model could inadvertently shift their primary service location out of a mandatory geographic area, risking exception or eligibility loss. Organizations should monitor episode volumes quarterly through the enhanced data feedback reporting tools CMS intends to provide.
Termination Authority Creates Unappealable Revenue Loss Risk
The 2027 final rule introduced a new CMS termination authority: CMS may terminate an ASM participant on grounds for remedial action or if continued participation is inconsistent with the model or applicable law. Upon termination, the participant loses all model waivers (MIPS exemption, telehealth geographic waiver) and safe harbor protections for remuneration attributable to the period specified in the termination notice. Because payment adjustments follow the participant to new organizations even after a performance year ends—a participant terminated after Year 1 could still receive a negative payment adjustment in 2029 based on Year 1 performance—there is no clean exit mechanism that eliminates prior-year financial liability. Compliance risks that could trigger remedial action include audit findings on quality measure falsification, CCA documentation deficiencies, beneficiary engagement incentive violations (the $1,000 per-patient cap; the $75 technology-ownership threshold), or failure to comply with data sharing agreement terms at 42 CFR §512.760. Organizations should establish internal ASM compliance programs with audit-ready documentation protocols before January 1, 2027 to minimize termination exposure across all five performance years.